We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Avacta
Targeting the tumour microenvironment with pre|CISIONScancell
Cohort 1 SCOPE data confirms SCIB1 response ratesArecor Therapeutics
AT220 sales building momentumAvacta
Next gen pre|CISION data unveiled at triple meetingOxford BioDynamics
Commercialising cutting edge diagnosticsScancell
SCOPE readouts in sight; SCIB1 data in Q424ANGLE
H124: renewed near-term focus on Pharma ServicesAvacta
H124 interims: a time to reflect on progress achievedArecor Therapeutics
H124: Focus on next steps for diabetes and obesityHUTCHMED
Flow of catalysts continues, with more into 2025